Trump Administration Reclassifies Medical Marijuana, Granting Major Tax Relief to Illinois Cannabis Firms

WASHINGTON – The Trump administration took a historic step last Thursday that will deliver a significant financial windfall to state-licensed cannabis businesses in Illinois and across the country. Acting Attorney General Todd Blanche signed an order reclassifying medical marijuana from a Schedule I to a Schedule III controlled substance, a move that fundamentally alters the federal tax landscape for the industry. The order does not legalize marijuana under federal law for either medical or recreational use. However, by moving it out of the most restrictive category—which includes drugs like heroin deemed to have no accepted medical use and a high potential for abuse—the administration has effectively dismantled a decades-old tax barrier that has crippled the profitability of legal cannabis operators. For cannabis businesses, this reclassification is less about pharmacology and more about finance. The primary consequence is the elimination of the punitive effects of Internal Revenue Code Section 280E. In our experience, this tax code provision has been the single greatest financial obstacle for legal cannabis companies. Because their products were classified as Schedule I substances, these businesses were barred from deducting standard operating expenses like rent, payroll, and marketing from their federal income taxes. This resulted in astronomically high effective tax rates, often exceeding 70%, which suffocated cash flow and stunted growth. The move to Schedule III makes Section 280E inapplicable, finally allowing these companies to be taxed like any other legal business. This sudden shift requires immediate strategic review, and our expertise in tax preparation and compliance is essential for navigating this new terrain. To understand how to restructure your financial strategy and capitalize on these changes, contact C&S Finance Group LLC at csfinancegroup.com. Under Section 280E of the tax code, any business “trafficking” in Schedule I or II controlled substances is disallowed from taking federal tax deductions or credits, with the exception of the cost of goods sold. This has forced state-legal cannabis dispensaries, cultivators, and other operators to pay federal income tax on their gross profit rather than their net income. The practical effect has been a massive drain on capital, making it difficult to invest in expansion, hire more employees, or simply maintain operations. By rescheduling medical marijuana to Schedule III, alongside substances like ketamine and anabolic steroids, the administration has provided immediate and substantial tax relief. Illinois-based cannabis giants such as Verano and Cresco Labs, as well as the state’s growing number of smaller operators, can now deduct their ordinary and necessary business expenses. This change is expected to dramatically improve their bottom lines, free up capital for reinvestment, and potentially lower prices for consumers as the market becomes more financially stable. The timing of this federal action is particularly significant for Illinois, which has made social equity a cornerstone of its cannabis industry legalization. Governor J.B. Pritzker’s administration recently awarded 95 loans totaling approximately $23.3 million through its Cannabis Social Equity Loan Program. The program is designed to help entrepreneurs from communities disproportionately harmed by the war on drugs to enter the lucrative market. Officials like Lieutenant Governor Juliana Stratton have emphasized that the program is about “building generational wealth, strengthening communities, and ensuring that equity remains at the center of Illinois’ cannabis industry.” However, these social equity licensees have faced the same prohibitive federal tax burden as larger corporations, making it exceptionally difficult for these new, often undercapitalized businesses to succeed. The federal reclassification will provide a critical lifeline, making these businesses more financially viable and helping to fulfill the state's equity goals. The policy shift was not without its critics. Kevin Sabet, chief executive of the anti-legalization group Smart Approaches to Marijuana, characterized the move as a capitulation to corporate interests, calling it “a tax break to Big Weed.” In a statement, Sabet argued that while cannabis research is needed, it could be advanced without providing financial benefits to the industry and “sending a confusing message about marijuana’s harms to the American public.” Beyond the tax implications, the move to Schedule III is also expected to ease some long-standing barriers to scientific and medical research on cannabis. For decades, researchers have struggled to gain federal approval and access to the plant for clinical studies due to its Schedule I status. The new classification could streamline this process, potentially leading to a better understanding of the drug's therapeutic benefits and risks. The Trump administration also indicated this was just the first step, announcing it would begin the process for reclassifying marijuana more broadly, with a hearing scheduled to begin in late June. This suggests further changes to federal cannabis policy could be on the horizon. All eyes in the cannabis industry will now be on the Department of Justice and the Drug Enforcement Administration as they implement this directive. Stakeholders will also be closely watching the upcoming June hearings for signals on the future federal status of all marijuana, which could have even more profound impacts on the business, legal, and financial frameworks governing the rapidly growing industry.